Back to Search Start Over

Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2

Authors :
Katrina M Wood
Stephania Bitetti
Mohammed Zarhrate
Rafiqul Hussain
Vicky Brocklebank
Meghan Acres
Vincent Bondet
Ruyue Sun
Tracy A Briggs
Rui Chen
John H. Livingston
Richard E. Randall
Robert Wynn
Claire L. Harris
Darragh Duffy
Cécile Fourrage
Florian Gothe
Christopher J A Duncan
Sophie Hambleton
Stephen M. Hughes
Karin R. Engelhardt
Julija Pavaine
Leo A. H. Zeef
Jonathan Coxhead
Dan F. Young
Yanick J. Crow
Aneta Mikulasova
Victoria G. Shuttleworth
Bronte M. Corner
Gillian I. Rice
Edmund Cheesman
Barbara A. Innes
Ronnie Wright
David J. Kavanagh
Angela Grainger
Simon C. Lovell
Andrew J. Skelton
Benjamin J. Thompson
Newcastle University [Newcastle]
University of Manchester [Manchester]
Ludwig-Maximilians-Universität München (LMU)
University of St Andrews [Scotland]
Immunobiologie des Cellules dendritiques
Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
University of Leeds
Central Manchester University Hospitals NHS Foundation Trust
Royal Manchester Children's Hospital
Imagine - Institut des maladies génétiques (IMAGINE - U1163)
Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Newcastle Upon Tyne Hospitals NHS Foundation Trust
Université Paris Descartes - Paris 5 (UPD5)
University of Edinburgh
British Infection Association (to C.J.A.D.), Wellcome Trust [211153/Z/18/Z (to C.J.A.D.), 207556/Z/17/Z (S.H.), and 101788/Z/13/Z (to D.F.Y. and R.E.R.)], Sir Jules Thorn Trust [12/JTA (to S.H.)], UK National Institute of Health Research [TRF-2016-09-002 (to T.A.B.)], NIHR Manchester Biomedical Resource Centre (to T.A.B.), Medical Research Foundation (to T.A.B.), Medical Research Council [MRC, MR/N013840/1 (to B.J.T.)], MRC/Kidney Research UK [MR/R000913/1 (to Vicky Brocklebank)], Deutsche Forschungsgemeinschaft [GO 2955/1-1 (to F.G.)], Agence Nationale de la Recherche [ANR-10-IAHU-01 (to Y.J.C.) and CE17001002 (to Y.J.C. and D.D.)], European Research Council [GA 309449 (Y.J.C.)
786142-E-T1IFNs], Newcastle University (to C.J.A.D.), and ImmunoQure for provision of antibodies (Y.J.C. and D.D.). C.L.H. and R.S. were funded by start-up funding from Newcastle University. D.K. has received funding from the Medical Research Council, Wellcome Trust, Kidney Research UK, Macular Society, NCKRF, AMD Society, and Complement UK
honoraria for consultancy work from Alexion Pharmaceuticals, Apellis Pharmaceuticals, Novartis, and Idorsia
and is a director of and scientific advisor to Gyroscope Therapeutics.
We are grateful to the patients and our thoughts are with their family
ANR-10-IAHU-0001,Imagine,Institut Hospitalo-Universitaire Imagine(2010)
European Project: 309449,EC:FP7:ERC,ERC-2012-StG_20111109,T1-IFN(2013)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris]
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut des Maladies Génétiques Imagine [Paris]
Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)
ANR-10-IAHU-0001/10-IAHU-0001,Imagine,Imagine(2010)
Source :
Rice, G, Lovell, S, Pavaine, J, Wright, R, Zeef, L, Hambleton, S, Briggs, T & et al. 2019, ' Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2 ', Science Immunology, vol. 4, no. 42, eaav7501 . https://doi.org/10.1126/sciimmunol.aav7501, Duncan, C J A, Thompson, B, Chen, R, Rice, G I, Gothe, F, Young, D F, Lovell, S C, Shuttleworth, V G, Brocklebank, V, Corner, B, Skelton, A J, Bondet, V, Coxhead, J, Duffy, D, Fourrage, C, Livingston, J H, Pavaine, J, Cheesman, E, Bitetti, S, Grainger, A, Acres, M, Innes, B A, Mikulasova, A, Sun, R, Hussain, R, Wright, R, Wynn, R, Zarhrate, M, Zeef, L A H, Wood, K M, Hughes, S M, Harris, C L, Engelhardt, K R, Crow, Y, Randall, R E, Kavanagh, D, Hambleton, S & Briggs, T A 2019, ' Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2 ', Science Immunology . https://doi.org/10.1126/sciimmunol.aav7501, Science Immunology, Science Immunology, 2019, 4 (42), pp.eaav7501. ⟨10.1126/sciimmunol.aav7501⟩, Science Immunology, American Association for the Advancement of Science, 2019, 4 (42), pp.eaav7501. ⟨10.1126/sciimmunol.aav7501⟩
Publication Year :
2019

Abstract

International audience; Excessive type I interferon (IFNα/β) activity is implicated in a spectrum of human disease, yet its direct role remains to be conclusively proven. We investigated two siblings with severe early-onset autoinflammatory disease and an elevated IFN signature. Whole-exome sequencing revealed a shared homozygous missense Arg148Trp variant in STAT2, a transcription factor that functions exclusively downstream of innate IFNs. Cells bearing STAT2R148W in homozygosity (but not heterozygosity) were hypersensitive to IFNα/β, which manifest as prolonged Janus kinase-signal transducers and activators of transcription (STAT) signaling and transcriptional activation. We show that this gain of IFN activity results from the failure of mutant STAT2R148W to interact with ubiquitin-specific protease 18, a key STAT2-dependent negative regulator of IFNα/β signaling. These observations reveal an essential in vivo function of STAT2 in the regulation of human IFNα/β signaling, providing concrete evidence of the serious pathological consequences of unrestrained IFNα/β activity and supporting efforts to target this pathway therapeutically in IFN-associated disease.

Details

Language :
English
ISSN :
24709468
Database :
OpenAIRE
Journal :
Rice, G, Lovell, S, Pavaine, J, Wright, R, Zeef, L, Hambleton, S, Briggs, T & et al. 2019, ' Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2 ', Science Immunology, vol. 4, no. 42, eaav7501 . https://doi.org/10.1126/sciimmunol.aav7501, Duncan, C J A, Thompson, B, Chen, R, Rice, G I, Gothe, F, Young, D F, Lovell, S C, Shuttleworth, V G, Brocklebank, V, Corner, B, Skelton, A J, Bondet, V, Coxhead, J, Duffy, D, Fourrage, C, Livingston, J H, Pavaine, J, Cheesman, E, Bitetti, S, Grainger, A, Acres, M, Innes, B A, Mikulasova, A, Sun, R, Hussain, R, Wright, R, Wynn, R, Zarhrate, M, Zeef, L A H, Wood, K M, Hughes, S M, Harris, C L, Engelhardt, K R, Crow, Y, Randall, R E, Kavanagh, D, Hambleton, S & Briggs, T A 2019, ' Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2 ', Science Immunology . https://doi.org/10.1126/sciimmunol.aav7501, Science Immunology, Science Immunology, 2019, 4 (42), pp.eaav7501. ⟨10.1126/sciimmunol.aav7501⟩, Science Immunology, American Association for the Advancement of Science, 2019, 4 (42), pp.eaav7501. ⟨10.1126/sciimmunol.aav7501⟩
Accession number :
edsair.doi.dedup.....b75b99ad822c9b4f4b821ead0cffb9e2